The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Privately held CHO Plus, Inc. announced today a project agreement awarded from the Biomedical Advanced Research and Development Authority ...
CHO Plus was awarded a project agreement from the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) for up to ...
BOSTON & SAN CARLOS, Calif.--(BUSINESS WIRE)--Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System ...
Aragen Biologics launched CHOMax™, a new cell line development and early manufacturing platform that the company says supports an integrated path from DNA to IND-enabling clinical supply for suitable ...
This article is based on a poster originally authored by Julia Scherzinger, Daniel Türk, and Fernando Aprile-Garcia from CYTENA GmbH. There is constant pressure to reduce timelines in mammalian cell ...
Advances in cell line engineering and microfluidic technologies offer substantial opportunities to shorten timelines in cell line development (CLD). However, as with any innovation, optimizing these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results